FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

House Dems Seek Answers on FDA Vaccine Memo

Top House Democrats demand FDA provide documents and explanations after revelations that a senior FDA official circulated new vaccine development guid...

latest-news-card-1
Biologics

Petition Urges FDA to Overhaul Biosimilar Approval Rules

A biosimilars scholar files a citizen petition urging FDA to dramatically streamline and modernize its biosimilar approval requirements.

latest-news-card-1
Human Drugs

FDA Delays Safety Review of Abortion Pill Mifepristone

FDA postpones a promised safety review of the abortion drug mifepristone and is now not likely to be released until after the 2026 midterm elections.

latest-news-card-1
Human Drugs

BioNTech, OncoC4 See Good Survival Data for Lung Cancer Drug

BioNTech and OncoC4 say their investigational immunotherapy gotistobart significantly extended survival for certain patients with advanced squamous no...

latest-news-card-1
Human Drugs

FDA Delays Decision on Agios Mitapivat sNDA for Thalassemia

FDA delays its review decision on an Agios Pharmaceuticals supplemental NDA for mitapivat, its oral therapy for adults with both transfusion-dependent...

latest-news-card-1
Human Drugs

Dyne Reports Strong Dystrophin Gains in Duchenne Study

Dyne Therapeutics reports positive topline results from its Phase 1/2 DELIVER trial of z-rostudirsen (DYNE-251), saying the investigational exon-skipp...

latest-news-card-1
Biologics

FDA OKs 1st Cellular Therapy for Severe Aplastic Anemia

FDA approves Gamida Cells Omisirge, the first cellular therapy authorized to treat patients with severe aplastic anemia.

latest-news-card-1
Human Drugs

Device Compliance Official Flags Quality Gaps, Rising Enforcement

A senior CDRH compliance official warns industry that persistent shortcomings in complaint handling, corrective actions, and medical device reporting ...

latest-news-card-1
Human Drugs

Breyanzi OKd for Hard-to-Treat Marginal Zone Lymphoma

FDA approves Juno Therapeutics CAR-T therapy lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory marginal zone lymphoma.

latest-news-card-1
Human Drugs

Praxis Epilepsy Drug Study Stopped for Positive Efficacy

Praxis Precision Medicines says its experimental epilepsy drug relutrigine produced positive results in a key study, prompting an independent committe...